Clinical observation on the effect of Kang' ai injection combined with transcatheter arterial chemoembolization on hepatocellular carcinoma in 36 patients
10.3781/j.issn.1000-7431.2008.11.021
- Author:
Jian-Zhong YI
1
Author Information
1. Department of General Surgery
- Publication Type:Journal Article
- Keywords:
Cancer;
Chemotherapy;
Kang' ai-injecton;
Liver neoplasms;
Regional perfusion
- From:
Tumor
2008;28(11):997-1000
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To observe the clinical efficacy of Kang' ai injection combined with transcatheter arterial chemoembolization (TACE) on hepatocellular carcinoma (HCC). Methods: All of 67 patients with HCC were divided into two groups: the observation group (n = 36) and the control group (n = 31). Control group received TACE therapy only, and the observation group was given Kang' ai injection combined with TACE. The response rate (RR), KPS scores, body weight, and adverse reaction were observed. Results: The short-term efficacies of observation group and control group were 44.4% and 41.9%, respectively. The difference was not significant (P >0.05). The KPS score of the observation group was elevated after treatment, and the difference was significant (P < 0.05). But the KPS score of the control group tended to decrease after treatment, but there was no significant difference (P >0.05). The body weight was not significantly different before and after treatment in the 2 groups (P >0.05). The occurrence rate of adverse drug reaction such as leucopenia, hemoglobin decrease, and liver function damage were lower in the observation group than that in the control group (P <0.05). The incidencs of thrombocytopenia, nausea or vomiting, and renal function damage had no significant difference between the two groups (P >0.05). Conclusion: Kang' ai injection combined with TACE improves the life quality of patients and decreases adverse reactions induced by chemotherapy.
